C2 PHARMA, a global manufacturer and supplier of ophthalmic and niche active pharmaceutical ingredients (APIs), is expanding global access to its portfolio of APIs with new regulatory submissions and approvals. Earlier this year, the company received a CEP for Cyclopentolate Hydrochloride and recently a C-DMF for Digoxin, supporting its position in ophthalmic and niche APIs.    Along with the C-DMF and CEP approvals, the most recent submissions include:   o   Brimonidine Tartrate o   CADIFA...